头对头“恩美曲妥珠单抗”!康宁杰瑞 HER2 双抗 ADC 新启动一项 III 期临床

Insight数据库
06 Feb

2 月 5 日,药物临床试验登记与信息公示平台官网显示,康宁杰瑞登记了一项 JSKN003 对比恩美曲妥珠单抗治疗HER2 阳性晚期乳腺癌的 III 期研究(CTR20250049)。截图来源:药物临床试验登记与信息公示平台这是一项 JSKN003 对比恩美曲妥珠单抗(T-DM1,HER2 ADC)治疗 HER2 阳性晚期乳腺癌的有效性和安全性的随机、对照、开放、多中心、III 期临床研究,主要...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10